-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter

Equities research analysts expect Endologix, Inc. (NASDAQ:ELGX) to announce earnings of ($0.22) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Endologix’s earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.17). Endologix also reported earnings of ($0.22) per share during the same quarter last year. The business is expected to issue its next quarterly earnings results after the market closes on Wednesday, February 21st.

On average, analysts expect that Endologix will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.66) to ($0.56). For the next year, analysts expect that the company will post earnings of ($0.50) per share, with EPS estimates ranging from ($0.53) to ($0.46). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Endologix.

Several equities analysts recently commented on the company. BidaskClub upgraded Endologix from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research cut Endologix from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Stifel Nicolaus reduced their target price on Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a research report on Wednesday, November 8th. Canaccord Genuity reaffirmed a “hold” rating and set a $5.00 price target on shares of Endologix in a research note on Wednesday, November 8th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Endologix in a research note on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company’s stock. Endologix presently has a consensus rating of “Hold” and an average target price of $5.41.

A number of hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company lifted its stake in Endologix by 4.3% during the second quarter. The Manufacturers Life Insurance Company now owns 66,890 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 2,738 shares during the last quarter. Voya Investment Management LLC lifted its stake in Endologix by 16.4% during the second quarter. Voya Investment Management LLC now owns 38,910 shares of the medical instruments supplier’s stock worth $189,000 after purchasing an additional 5,471 shares during the last quarter. Alliancebernstein L.P. lifted its stake in shares of Endologix by 11.5% in the 2nd quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock valued at $529,000 after acquiring an additional 11,200 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Endologix by 3.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 350,063 shares of the medical instruments supplier’s stock valued at $1,873,000 after acquiring an additional 12,825 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of Endologix by 14.3% in the 2nd quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock valued at $670,000 after acquiring an additional 17,300 shares during the last quarter.

Endologix (NASDAQ ELGX) traded down $0.17 during trading on Wednesday, reaching $4.04. The company had a trading volume of 472,500 shares, compared to its average volume of 655,873. Endologix has a twelve month low of $3.89 and a twelve month high of $7.66. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90. The stock has a market capitalization of $351.34, a PE ratio of -4.34 and a beta of 0.42.

ILLEGAL ACTIVITY NOTICE: “-$0.22 EPS Expected for Endologix, Inc. (ELGX) This Quarter” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/0-22-eps-expected-for-endologix-inc-elgx-this-quarter.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply